MX2023002087A - Agonistas del receptor crf2 y su uso en terapia. - Google Patents

Agonistas del receptor crf2 y su uso en terapia.

Info

Publication number
MX2023002087A
MX2023002087A MX2023002087A MX2023002087A MX2023002087A MX 2023002087 A MX2023002087 A MX 2023002087A MX 2023002087 A MX2023002087 A MX 2023002087A MX 2023002087 A MX2023002087 A MX 2023002087A MX 2023002087 A MX2023002087 A MX 2023002087A
Authority
MX
Mexico
Prior art keywords
therapy
receptor agonists
crf2
crf2 receptor
agonists
Prior art date
Application number
MX2023002087A
Other languages
English (en)
Spanish (es)
Inventor
Andreas Evers
Philip Janiak
Nis Halland
Ralf Elvert
Elisabetta Bianchi
Alessia Santoprete
Ziyu Li
Stephane Illiano
Laurence Lucats
Laetitia Ledein
Philippe Beauverger
Marie Laure Ozoux
Daniela Roversi
Martina Tripepi
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2023002087A publication Critical patent/MX2023002087A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023002087A 2020-08-19 2021-08-18 Agonistas del receptor crf2 y su uso en terapia. MX2023002087A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20315387 2020-08-19
PCT/EP2021/072923 WO2022038179A1 (en) 2020-08-19 2021-08-18 Crf2 receptor agonists and their use in therapy

Publications (1)

Publication Number Publication Date
MX2023002087A true MX2023002087A (es) 2023-03-23

Family

ID=72615799

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002087A MX2023002087A (es) 2020-08-19 2021-08-18 Agonistas del receptor crf2 y su uso en terapia.

Country Status (16)

Country Link
US (1) US20250243255A1 (enExample)
EP (2) EP4199946B1 (enExample)
JP (1) JP7832927B2 (enExample)
KR (1) KR20230051583A (enExample)
CN (1) CN116472053A (enExample)
AU (1) AU2021328673A1 (enExample)
CA (1) CA3192032A1 (enExample)
ES (1) ES2988026T3 (enExample)
HR (1) HRP20240906T1 (enExample)
HU (1) HUE066991T2 (enExample)
IL (1) IL300464A (enExample)
IS (1) IS3063B (enExample)
MX (1) MX2023002087A (enExample)
PL (1) PL4199946T3 (enExample)
WO (1) WO2022038179A1 (enExample)
ZA (1) ZA202301784B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
EP4234574A1 (en) * 2022-02-23 2023-08-30 Corteria Pharmaceuticals Crf2 receptor agonists and their use in therapy
WO2025104264A1 (en) 2023-11-17 2025-05-22 Gubra A/S Hcrhr2 selective polypeptides
TW202544027A (zh) * 2024-04-19 2025-11-16 美商紐羅克里生物科學有限公司 促皮質素釋放因子受體２（ｃｒｆｒ２）促效劑
WO2025230248A1 (ko) * 2024-04-30 2025-11-06 한미약품 주식회사 Crf2 수용체 작용제와 그 아실화 결합체의 용도
WO2026064495A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
WO2026064486A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008047241A2 (en) * 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
JP5721432B2 (ja) 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
CN104356224A (zh) 2014-10-24 2015-02-18 杭州阿德莱诺泰制药技术有限公司 一种制备萨摩鲁泰的方法
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
WO2019140030A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy

Also Published As

Publication number Publication date
KR20230051583A (ko) 2023-04-18
HRP20240906T1 (hr) 2024-10-11
EP4199946A1 (en) 2023-06-28
ZA202301784B (en) 2024-01-31
EP4435001A3 (en) 2024-10-09
WO2022038179A1 (en) 2022-02-24
PL4199946T3 (pl) 2024-08-19
IL300464A (en) 2023-04-01
HUE066991T2 (hu) 2024-09-28
AU2021328673A1 (en) 2023-03-30
JP2023541798A (ja) 2023-10-04
CN116472053A (zh) 2023-07-21
JP7832927B2 (ja) 2026-03-18
EP4199946C0 (en) 2024-06-05
IS3063B (is) 2025-06-15
US20250243255A1 (en) 2025-07-31
EP4435001A2 (en) 2024-09-25
ES2988026T3 (es) 2024-11-19
CA3192032A1 (en) 2022-02-24
EP4199946B1 (en) 2024-06-05

Similar Documents

Publication Publication Date Title
MX2023002087A (es) Agonistas del receptor crf2 y su uso en terapia.
CO2023011071A2 (es) Agonistas del receptor gpcr, composiciones farmacéuticas que los comprenden y métodos para su uso
CL2019002777A1 (es) Compuestos que inhiben la proteína mcl-1.
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
CO2022010330A2 (es) Dosificación de gamma-hidroxibutirato (ghb)
CL2023000087A1 (es) Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral
MX2023012918A (es) Agonistas del receptor del péptido 1 similar al glucagón (glp-1) de bencimidazoilo, composiciones farmacéuticas que los comprenden y métodos para su uso.
DOP2021000198A (es) Compuestos y su uso en el tratamiento del cáncer
CO2023005188A2 (es) Compuestos y su uso en el tratamiento del cáncer
MX2021011209A (es) Novedosos inhibidores de molécula pequeña de factores de transcripción tead.
CL2021001325A1 (es) Ureas cíclicas.
CL2023000090A1 (es) Coagonistas de los receptores de glp-1 y gip
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
UY39969A (es) Ciertas octahidrofuro[3,4-b]pirazinas como moduladores del receptor de glp-1
ECSP045474A (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6
UY39968A (es) Ciertos 2,5-diazabiciclo[4.2.0]octanos como moduladores del receptor de glp-1
MX2021004566A (es) Compuestos terapeuticos.
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
CO6280470A2 (es) Bis-piridilpiridonas como antaginistas del receptor 1 de la hormona concentradora de la melanina
CL2023003893A1 (es) Semaglutida para el tratamiento de esteatohepatitis no alcohólica.
MX2024010296A (es) Agonistas del receptor de crf2 y su uso en terapia.
MX390157B (es) Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
CL2022001779A1 (es) Composiciones que comprenden aminoácidos para la prevención y/o el tratamiento del cáncer
CL2022002589A1 (es) Tratamiento de trastornos respiratorios